TLPPF (Telix Pharmaceuticals) Tariff Resilience Score: 6/10 (As of Jun. 30, 2026)


TLPPF Telix Pharmaceuticals Ltd TLPPF
66 GF Score
Price $11.00
GF Value $28.35
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Telix Pharmaceuticals Tariff Resilience Score?

Telix Pharmaceuticals TLPPF 66 Tariff Resilience Score is 6 as of Jun. 30, 2026. GuruFocus rates TLPPF with a GF Score™ of 66/100 and a GF Value™ of $28.35 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,375 Biotechnology companies, Telix Pharmaceuticals ranks better than 76% on this metric.

Telix Pharmaceuticals has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Telix Pharmaceuticals has Telix Pharmaceuticals' reliance on international supply chains for radiopharmaceuticals exposes it to tariffs. However, healthcare industry exemptions and strategic partnerships offer some protection.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Telix Pharmaceuticals might have Average Resilient.

Telix Pharmaceuticals  (OTCPK:TLPPF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Telix Pharmaceuticals Tariff Resilience Score Related Terms

TLPPF vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Telix Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Telix Pharmaceuticals Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Telix Pharmaceuticals's Tariff Resilience Score falls into.


TLPPF
66GF Score
Telix Pharmaceuticals Ltd TLPPF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Telix Pharmaceuticals (TLPPF) has a Tariff Resilience Score of 6 as of Jun. 30, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Telix Pharmaceuticals ranks #330 out of 1375 companies in the Biotechnology industry, placing it in the top 24%.
Is Telix Pharmaceuticals' Tariff Resilience Score too high?
Telix Pharmaceuticals' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Telix Pharmaceuticals' value of 6 is 50% above this industry median. Based on the distribution chart, Telix Pharmaceuticals ranks #330 out of 1375 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Telix Pharmaceuticals has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Telix Pharmaceuticals' Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Telix Pharmaceuticals ranks #330 out of 1375 companies for Tariff Resilience Score. This places Telix Pharmaceuticals in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Telix Pharmaceuticals' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,375 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Telix Pharmaceuticals's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Telix Pharmaceuticals's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Telix Pharmaceuticals (TLPPF) is currently considered Possible Value Trap. The stock's GF Value™ is $28.35, compared to a current price of $11.00 — trading 61.2% below its estimated fair value. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Telix Pharmaceuticals' overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Telix Pharmaceuticals (TLPPF), the current Tariff Resilience Score is 6 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Telix Pharmaceuticals (TLPPF) Overvalued in 2026?

Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued. The current stock price of $11.00 is trading 61.2% below its estimated GF Value™ of $28.35. GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.

Key valuation signals for TLPPF:

  • Tariff Resilience Score: 6
  • GF Value™: $28.35 vs. price of $11.00 (61.2% below fair value)
  • GF Score™: 66/100 with 6 warning signs
  • Industry Position: 50% above the Biotechnology median (#330 of 1375)

No single metric tells the full story. See the TLPPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Telix Pharmaceuticals Business Description

Address 55 Flemington Road, Level 4, North Melbourne, Melbourne, VIC, AUS, 3051
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
66GF Score

Get the complete analysis for TLPPF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.00
Price
$28.35
GF Value